Results from the study were presented at the 8th International AIDS Society on HIV Pathogenesis, Treatment and Prevention (IAS 2015) on July 19-22.
Overall, 97% of the patients achieved SVR 12 weeks after the end of treatment. Approximately 70% of patients undergoing the study had cirrhosis whereas approximately 15-20% of patients in clinical trials had cirrhosis.
Researchers found that extending the treatment time or adding ribavirin only very slightly changed SVR results. Of the 39 patients receiving Daklinza and Sovaldi for 12 weeks, 98% achieved SVR, while 97% of the 89 patients receiving the combination for 24 weeks achieved SVR. Six patients who were treated with the combination and ribavirin for 12 weeks all received SVR as did all eight patients undergoing the same treatment for 24 weeks.
In addition, the results remained about the same across the three genotypes included in the study. SVR rates were 98% for genotype 1, 100% for genotype 3, and 96% for genotype 4. For patients with cirrhosis, SVR ranged from 95-100%.
During the study, nine patients died, seven of which were determined unrelated to the treatment. The cause of the remaining two, one multi-organ failure and one hepato-renal failure, were not clear. There were 22 adverse events reported during the study, but all were determined unrelated to the treatment with the exception of two. Only two patients ended treatment early due to adverse side effects.
Researchers said there were no indications the HCV treatment had any negative effect on the HIV treatment.1,2